Raffaella Longarini

1.3k total citations
16 papers, 409 citations indexed

About

Raffaella Longarini is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Raffaella Longarini has authored 16 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Raffaella Longarini's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Genomics and Diagnostics (4 papers) and Estrogen and related hormone effects (3 papers). Raffaella Longarini is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Genomics and Diagnostics (4 papers) and Estrogen and related hormone effects (3 papers). Raffaella Longarini collaborates with scholars based in Italy, United States and Switzerland. Raffaella Longarini's co-authors include Emilio Bajetta, Luigi Celio, Roberto Buzzoni, Sara Massironi, Pietro Invernizzi, Roberta Rossi, Alessandra Elvevi, Luigi Mariani, Nicoletta Zilembo and Giuseppe Procopio and has published in prestigious journals such as Journal of Clinical Oncology, Biomedicine & Pharmacotherapy and Cells.

In The Last Decade

Raffaella Longarini

16 papers receiving 405 citations

Peers

Countries citing papers authored by Raffaella Longarini

Since Specialization

Citations

This map shows the geographic impact of Raffaella Longarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raffaella Longarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raffaella Longarini more than expected).

Fields of papers citing papers by Raffaella Longarini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raffaella Longarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raffaella Longarini. The network helps show where Raffaella Longarini may publish in the future.

Co-authorship network of co-authors of Raffaella Longarini

This figure shows the co-authorship network connecting the top 25 collaborators of Raffaella Longarini. A scholar is included among the top collaborators of Raffaella Longarini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raffaella Longarini. Raffaella Longarini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Colorectal Cancer Pulmonary Metastasectomy: When, Why and How 2024 ·Cancers ·Francesco Petrella, (unknown), Maria Sibilia, (unknown), Raffaella Longarini, (unknown), (unknown), Lidia Libretti, (unknown), (unknown), (unknown), (unknown), Diego Cortinovis	4
2	Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives 2024 ·Cancers ·Francesca Corti, Roberta Rossi, (unknown), (unknown), (unknown), Sara Pusceddu, Jorgelina Coppa, (unknown), (unknown), Raffaella Longarini, Diego Cortinovis	2
3	Clinical treatment of cholangiocarcinoma: an updated comprehensive review 2022 ·Annals of Hepatology ·Alessandra Elvevi, (unknown), Miki Scaravaglio, Roberta Rossi, Raffaella Longarini, (unknown), Laura Cristoferi, Antonio Ciaccio, Diego Cortinovis, Pietro Invernizzi, Sara Massironi	84
4	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 2020 ·Cells ·Sara Massironi, Lorenzo Pilla, Alessandra Elvevi, Raffaella Longarini, Roberta Rossi, Paolo Bidoli, Pietro Invernizzi	65
5	Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 2020 ·European Journal of Cancer Care ·Marco Bani, Emanuela Rossi, Diego Cortinovis, Selena Russo, (unknown), Marij A. Hillen, Stefania Canova, (unknown), Raffaella Longarini, Marina Elena Cazzaniga, Paolo Bidoli, Maria Grazia Valsecchi, Maria Grazia Strepparava	4
6	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients. 2019 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Riccardo Lobefaro, Maria Antista, Rosalba Miceli, Alessandra Raimondi, Sara Lonardi, Lorenza Rimassa, (unknown), Iolanda Capone, Gabriella Farina, Raffaella Longarini, Stefania Mosconi, Andrea Sartore‐Bianchi, Gianluca Tomasello, Federica Perrone, Ludovic Barault, Massimo Milione, Federica Di Nicolantonio, Maria Di Bartolomeo, Filippo de Braud	1
7	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. 2018 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Federica Morano, Salvatore Corallo, Sara Lonardi, Chiara Cremolini, Lorenza Rimassa, Andrea Sartore‐Bianchi, Marco Tampellini, Sara Bustreo, Matteo Clavarezza, Roberto Murialdo, Alberto Zaniboni, Vincenzo Adamo, Gianluca Tomasello, Monica Giordano, Fausto Petrelli, Raffaella Longarini, Vittorina Zagonel, Maria Di Bartolomeo, Filippo de Braud	21
8	Open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients (pts) who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer (CRC). 2016 ·Journal of Clinical Oncology ·Rosa Berenato, Filippo Pietrantonio, Marta Caporale, Ilaria Bossi, Gianluca Tomasello, Stefania Mosconi, (unknown), Silvia Bozzarelli, Raffaella Longarini, Stefania Gori, Alberto Zaniboni, Alessandro Bertolini, Francesca Bergamo, Sandro Barni, Alessio Amatu, Daniele Fagnani, Maria Giulia Zampino, Federica Morano, Maria Di Bartolomeo, Filippo de Braud	1
9	First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study. 2016 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Marta Caporale, Rosa Berenato, Sara Lonardi, Roberto Murialdo, (unknown), Marco Tampellini, Alessandro Bertolini, Lorenza Rimassa, Chiara Cremolini, Elisa Giommoni, Gianluca Tomasello, Raffaella Longarini, Fausto Petrelli, Alberto Zaniboni, Enrico Cortesi, Andrea Sartore‐Bianchi, Ilaria Bossi, Maria Di Bartolomeo, Filippo de Braud	1
10	Immunotherapy options in metastatic renal cell cancer: where we are and where we are going 2006 ·Expert Review of Anticancer Therapy ·Rodolfo Passalacqua, Sebastiano Buti, Gianluca Tomasello, Raffaella Longarini, Matteo Brighenti, (unknown)	11
11	Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women 2005 ·Journal of Clinical Oncology ·Emilio Bajetta, Giuseppe Procopio, Luigi Celio, Luca Gattinoni, S. Della Torre, Luigi Mariani, Laura Catena, Riccardo Ricotta, Raffaella Longarini, Nicoletta Zilembo, Roberto Buzzoni	157
12	The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients 2004 ·Biomedicine & Pharmacotherapy ·Nicoletta Zilembo, Emilio Bajetta, E. Bichisao, Antonia Martinetti, Ignazia La Torre, Paolo Bidoli, Raffaella Longarini, (unknown), Ettore Seregni, Emilio Bombardieri	8
13	Prospective evaluation of estrogen receptor-β in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients 2004 ·Endocrine Related Cancer ·Vera Cappelletti, Luigi Celio, Emilio Bajetta, (unknown), Raffaella Longarini, Patrizia Miodini, Raffaella Villa, Alessandra Fabbri, Luigi Mariani, Riccardo Giovanazzi, Emanuele Galante, Marco Greco, Maria Grazia Daidone	23
14	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? 2003 ·International Journal of Oncology ·Leonardo Ferrari, Emilio Bajetta, Antonia Martinetti, Luigi Celio, Raffaella Longarini, Ignazia La Torre, Roberto Buzzoni, Luca Gattinoni, Ettore Seregni, Emilio Bombardieri	10
15	Pemetrexed in gastric cancer: Clinical experience and future perspectives 2002 ·Seminars in Oncology ·Luigi Celio, Roberto Buzzoni, Raffaella Longarini, Alfonso Marchianò, Emilio Bajetta	7
16	Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer 2001 ·Tumori Journal ·Antonino Cassata, Giuseppe Procopio, (unknown), Leonardo Ferrari, Erminia Ferrario, Elena Beretta, Raffaella Longarini, (unknown), (unknown), Emilio Bajetta	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact